Active Biotech

April 28, 2011 02:45 ET

Active Biotech AB Interim Report January - March 2011

LUND, SWEDEN--(Marketwire - Apr 28, 2011) -


--  Laquinimod - complete results from Allegro Phase III trial presented
--  TASQ - Active Biotech and Ipsen enter into a broad partnership for the
    co-development and commercialization of TASQ in uro-oncology
--  ANYARA - ongoing Phase III study expected to be concluded in 2012
--  57-57 - orphan drug status granted
--  ISI - project proceeding according to plan
--  RhuDex™ - preparations for continued clinical development in
progress
--  Net sales SEK 2.7 M (2.8)
--  Operating loss SEK 70.9 M (loss: 51.0)
--  Loss after tax SEK 69.3 (loss: 53.5)
--  Loss per share for the period amounted to 1.02 (loss: 0.83)
--  Private placement of SEK 375 M completed

Active Biotech AB Interim Report January - March 2011:

http://hugin.info/1002/R/1509816/444684.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1509816]

Contact Information

  • For further information, please contact:

    Tomas Leanderson
    President and CEO
    Tel: +46 (0)46-19 20 95

    Goran Forsberg
    VP Investor Relations & Business Development
    Tel: +46 (0)46-19 11 54

    Hans Kolam
    CFO
    Tel. +46 (0)46-19 20 44

    Active Biotech AB
    (Corp. Reg. No. 556223-9227)
    PO Box 724, SE-220 07 Lund
    Tel: +46 (0)46-19 20 00
    Fax: +46 (0)46-19 11 00
    This report is also available at www.activebiotech.com